Abstract:
:The oral deoxyguanosine nucleoside analogue entecavir (Baraclude®) has potent activity against hepatitis B virus (HBV) and a high genetic barrier to resistance. This article reviews the clinical efficacy and tolerability of entecavir in the treatment of chronic hepatitis B in patients with decompensated liver disease, as well as summarizing its pharmacological properties. Entecavir 1 mg/day was more effective than adefovir dipivoxil 10 mg/day in the treatment of patients with chronic hepatitis B and decompensated liver disease, according to the results of a randomized, open-label, multicentre trial. Patients were either nucleos(t)ide naive or lamivudine experienced. The reduction from baseline in HBV DNA levels at week 24 (primary endpoint) was significantly greater with entecavir than with adefovir dipivoxil. The proportion of patients with HBV DNA levels of <300 copies/mL was also significantly greater with entecavir than with adefovir dipivoxil at weeks 24, 48 and 96, as was the proportion of patients with ALT normalization. Entecavir 0.5 or 1 mg/day, tenofovir disoproxil fumarate 300 mg/day and a fixed-dose combination of emtricitabine/tenofovir disoproxil fumarate 200 mg/300 mg per day were effective in the treatment of chronic hepatitis B in patients with decompensated liver disease, according to the 48-week analysis of a randomized, double-blind, multicentre trial, primarily designed to examine tolerability endpoints. In this trial, over one-third of patients had received previous therapy with lamivudine for ≥6 months. The efficacy of entecavir in treatment-naive patients with HBV-related decompensated cirrhosis did not significantly differ from that seen in patients with chronic hepatitis B or compensated cirrhosis (compensated group), according to the results of a prospective, nonrandomized study. After 6 or 12 months of entecavir treatment, there were no significant differences between the decompensated and compensated groups in virological, biochemical or serological endpoints. In patients with decompensated cirrhosis, significant improvements from baseline in liver function were seen after 12 months of entecavir therapy. Oral entecavir was generally well tolerated in patients with chronic hepatitis B and decompensated liver disease, with most of the reported treatment-emergent adverse events consistent with decompensated liver disease. In the trial primarily designed to examine tolerability endpoints, there was no significant difference between patients receiving entecavir and those receiving tenofovir disoproxil fumarate with or without emtricitabine in terms of the proportion of patients experiencing tolerability failure or the proportion of patients with confirmed increases in serum creatinine levels of ≥0.5 mg/dL above baseline or confirmed serum phosphorus levels of <2.0 mg/dL at week 48 (co-primary endpoints). It has been suggested that the risk of lactic acidosis associated with oral nucleos(t)ide analogue therapy is increased in patients with highly impaired liver function. However, only one case of lactic acidosis was reported among entecavir recipients across two clinical trials in patients with chronic hepatitis B and decompensated liver disease. Moreover, small studies found that the risk of lactic acidosis was not increased in patients with chronic hepatitis B and decompensated liver disease who received entecavir, compared with patients with non-HBV decompensated liver disease. In conclusion, entecavir is a valuable agent for the first-line treatment of chronic hepatitis B in patients with decompensated liver disease.
journal_name
Drugsjournal_title
Drugsauthors
Keating GMdoi
10.2165/11208510-000000000-00000subject
Has Abstractpub_date
2011-12-24 00:00:00pages
2511-29issue
18eissn
0012-6667issn
1179-1950pii
9journal_volume
71pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::Alprazolam is a triazolobenzodiazepine which is related to diazepam and other 1,4-benzodiazepines, and has a similar pharmacological profile. Relative to the newer benzodiazepines, alprazolam has an intermediate half-life of 10 to 12 hours in healthy young subjects. In placebo-controlled and double-blind comparative t...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-198427020-00002
更新日期:1984-02-01 00:00:00
abstract::Safety data have been gathered in US clinical trials of nabumetone on 1912 patients from August 1981 to May 1988. Dosing in the double-blind trials was 100 mg at bedtime, but in open-label trials patients could increase the dosage of nabumetone to 1500 or 2000 mg if required. Adverse experiences reported in the double...
journal_title:Drugs
pub_type: 临床试验,杂志文章
doi:10.2165/00003495-199000405-00008
更新日期:1990-01-01 00:00:00
abstract::The rationale for the use of nifedipine in patients with acute myocardial infarction (MI) is based on the various cardiovascular actions of the compound: reduction of myocardial oxygen consumption by attenuation of cardiac and vascular smooth muscle tension; augmentation of oxygen and substrate supply after increased ...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验,评审
doi:10.2165/00003495-199100422-00007
更新日期:1991-01-01 00:00:00
abstract:UNLABELLED:Patients with beta-thalassaemia and other transfusion-dependent diseases develop iron overload from chronic blood transfusions and require regular iron chelation to prevent potentially fatal iron-related complications. The only iron chelator currently widely available is deferoxamine, which is expensive and ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199958030-00021
更新日期:1999-09-01 00:00:00
abstract::In the table 'Key clinical trials of isatuximab (Sanofi)', in the left-hand column. ...
journal_title:Drugs
pub_type: 杂志文章,已发布勘误
doi:10.1007/s40265-020-01325-9
更新日期:2020-06-01 00:00:00
abstract::Intravenous susoctocog alfa (Obizur(®)) is a recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) product that has recently been approved for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). Intravenous susoctocog alfa was an effective and generally well to...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0576-1
更新日期:2016-05-01 00:00:00
abstract::The simplest response to the question, what is the prevalence of hypertension in the United States today?, is given by a currently popular slogan: 23,000,000 Americans have hypertension. It is clear that the problem is large in scale, but this figure alone is an insufficient guide to many practical issues. The prevale...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-197600111-00006
更新日期:1976-01-01 00:00:00
abstract::The emergence of antibiotic resistance is primarily due to excessive and often unnecessary use of antibiotics in humans and animals. Risk factors for the spread of resistant bacteria in hospitals and the community can be summarised as over-crowding, lapses in hygiene or poor infection control practices. Increasing ant...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199855030-00001
更新日期:1998-03-01 00:00:00
abstract::In human lung tissue in vitro, nedocromil sodium inhibited the release of histamine and leukotrienes induced by anti-IgE, as well as the contraction of isolated bronchi which followed this challenge. In the hamster cheek pouch in vivo, nedocromil sodium inhibited the inflammatory response induced by challenge with eit...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198900371-00013
更新日期:1989-01-01 00:00:00
abstract::Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin an...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-016-0666-0
更新日期:2017-01-01 00:00:00
abstract::During the last 2 decades, there has been a dramatic increase in the use of strong opioids for chronic non-cancer pain. This increase has been accompanied by a steep increase in abuse, misuse, and both fatal and non-fatal overdoses involving prescription opioids. The situation is already alarming in the US. Prescripti...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11635860-000000000-00000
更新日期:2012-09-10 00:00:00
abstract::For patients with superficial bladder tumours intravesical treatment or prophylaxis with thiotepa, doxorubicin, mitomycin C or Bacillus Calmette-Guerin has added a useful dimension to management, although the precise indications for each regimen remain to be better defined. For patients with metastatic bladder cancer ...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-198938020-00009
更新日期:1989-08-01 00:00:00
abstract::Hypertension is common in chronic renal disease and is a risk factor for the faster progression of renal damage, and reduction of blood pressure (BP) is an efficient way of preventing or slowing the progression of this damage. International guidelines recommend lowering BP to 140/90 mm Hg or less in patients with unco...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200565002-00005
更新日期:2005-01-01 00:00:00
abstract::Aflibercept (Eylea(®)) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus ma...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0421-y
更新日期:2015-07-01 00:00:00
abstract::The introduction of medications that target specific proinflammatory cytokines has revolutionized the management of patients with rheumatoid arthritis. The agents that antagonize the effects of tumour necrosis factor (TNF)-alpha -- infliximab, etanercept and adalimumab -- have consistently shown very good efficacy for...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868050-00003
更新日期:2008-01-01 00:00:00
abstract::Prostaglandin E2 (PGE2) is a potent stimulator of inflammation, and the inhibition of its synthesis is one possible mechanism of action of non-steroidal anti-inflammatory drugs (NSAIDs). We have investigated patients suffering from rheumatoid arthritis to determine how synovial fluid levels of PGE2 are affected by tia...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198800351-00004
更新日期:1988-01-01 00:00:00
abstract::Drug-resistant tuberculosis (DR-TB) is an emerging global health threat as treatment involves complex multiple drug regimens, which are longer and more toxic than standard therapy and yet have worse outcomes. In the presence of resistance to one or more first-line drugs, an alternative regimen should be designed. A ma...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/11585440-000000000-00000
更新日期:2011-05-07 00:00:00
abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial onset seizu...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11204490-000000000-00000
更新日期:2011-03-05 00:00:00
abstract::Since an earlier review in the Journal substantial additional data have accumulated, further clarifying the in vitro activity, pharmacokinetic profile, clinical efficacy and tolerability of teicoplanin. Recent therapeutic trials confirm the efficacy of teicoplanin in the treatment of microbiologically confirmed Gram-p...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199447050-00008
更新日期:1994-05-01 00:00:00
abstract::Pain is associated with emotional and physical suffering that severely impacts quality of life. Many guidelines for the treatment of moderate to severe cancer pain indicate the use of opioids. For a small proportion of the global population, opioids are readily accessible, but are consequently also subject to risk of ...
journal_title:Drugs
pub_type: 杂志文章
doi:10.1007/s40265-020-01342-8
更新日期:2020-08-01 00:00:00
abstract::Cephalosporins have a role in the treatment of gonorrhoea, and especially infections caused by strains that are penicillin-resistant, either because they produce plasmid-mediated beta-lactamase or they have chromosomally mediated diminished permeability or modified penicillin-binding proteins. Although none of the ora...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198700342-00013
更新日期:1987-01-01 00:00:00
abstract::Benzbromarone1 is a benzofuran derivative which lowers serum urate and increases urinary urate excretion in normal, hyperuricaemic and gouty subjects. In open short- and long-term studies benzbromarone reduced serum uric acid levels by one-third to one-half and maintained its effectiveness for periods of up to 8 years...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-197714050-00002
更新日期:1977-11-01 00:00:00
abstract::Through years of evolutionary selection pressures, organisms have developed potent toxins that coincidentally have marked antineoplastic activity. These natural products have been vital for the development of multiagent treatment regimens currently employed in cancer chemotherapy, and are used in the treatment of a va...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-015-0489-4
更新日期:2015-11-01 00:00:00
abstract::The incidence of infection in clean surgery (i.e. surgery with no major contamination of the operative site) should be less than 2%, although the incidence of postoperative infections can be higher in patients with various risk factors (namely insertion of foreign bodies, a compromised immune status or prolonged durat...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199700546-00008
更新日期:1997-01-01 00:00:00
abstract::Chronic obstructive pulmonary disease (COPD) is characterised by insidiously progressive airflow limitation. The necessarily multifactorial management programme should include smoking cessation, prevention of infections, bronchodilator and steroid therapy, supplemental oxygen, physical therapy, pulmonary rehabilitatio...
journal_title:Drugs
pub_type: 临床试验,杂志文章,评审
doi:10.2165/00003495-198938010-00007
更新日期:1989-07-01 00:00:00
abstract::In the past 2 decades, progressive improvements in the results of organ transplantation as a therapeutic strategy for patients with end-stage organ disease have been achieved due to greater insight into the immunobiology of graft rejection and better measures for surgical and medical management. It is now known that T...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199754040-00003
更新日期:1997-10-01 00:00:00
abstract::The pharmacokinetics of different formulations of glyceryl trinitrate, isosorbide dinitrate, isosorbide 5-mononitrate and isosorbide 2-mononitrate are reviewed. ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198700334-00004
更新日期:1987-01-01 00:00:00
abstract::Sulbactam is a semisynthetic beta-lactamase inhibitor which when combined with certain beta-lactam antibacterials extends their activity against bacteria that are normally resistant to the antibiotic due to production of beta-lactamases. In combination with ampicillin it extends the antibacterial activity of ampicilli...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198733060-00003
更新日期:1987-06-01 00:00:00
abstract::Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A. Subcutaneous emicizumab is approved in several countries, including in the USA and...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01200-2
更新日期:2019-10-01 00:00:00
abstract::Bronchial asthma is an inflammatory disease. The characteristic pathological features of epithelial cell loss, goblet cell hyperplasia, increased deposition of collagen beneath the basement membrane, mast cell degranulation, and inflammatory cell infiltration of the mucosa are not limited to fatal asthma. Similar infl...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198900371-00021
更新日期:1989-01-01 00:00:00